Cerulean Pharmaceuticals Obtains $10,000,000 Series B Funding

  • Feed Type
  • Date
  • Company Name
    Cerulean Pharmaceuticals
  • Mailing Address
    161 First Street Cambridge, MA 02142
  • Company Description
    Within the field of nanopharmaceuticals, Cerulean Pharma is uniquely focused on a next-generation approach we call Nanobiology. Cerulean’s nanobiology-based drug development is based on a deep understanding of the complex biological microenvironment of human disease combined with engineering therapies on a nanoscale, enabling the creation of breakthrough drugs that optimally target the root causes of disease.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    Cerulean intends to use the proceeds from the financing to advance the clinical development of IT-101, a cyclodextrin-based camptothecin nanoparticle recently in-licensed from Calando Pharmaceuticals, Inc., and to accelerate the preclinical development of nanoparticle-based drugs using both Cerulean’s pre-existing nanoparticle-based technology as well as the in-licensed cyclodextrin-based nanoparticle technology.
  • M&A Terms
  • Venture Investor
    Polaris Venture Partners
  • Venture Investor
  • Venture Investor
    Lux Capital
  • Venture Investor
    Bessemer Venture Partners

Trending on Xconomy